Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
P/E ratio for Avidity Biosciences, Inc. (RNA)
P/E ratio as of 2023: -3.11
According to Avidity Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.11. At the end of 2022 the company had a P/E ratio of -6.85.
P/E ratio history for Avidity Biosciences, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -3.11 |
| 2022 | -6.85 |
| 2021 | -8.39 |
| 2020 | -12.57 |
| 2019 | -33.28 |
| 2018 | -49.39 |